HCA Healthcare Inc (HCA) PT Raised to $482 at RBC Capital Amid Strong Demand

RBC Capital analyst Ben Hendrix raised the price target on HCA Healthcare Inc (NYSE: HCA) to $482.00 (from $449.00) while maintaining an Outperform rating.

The analyst commented: "Strong demand and investments in patient access lend confidence in 2026 growth, even ex-subsidies; We were pleased to see HCA shares advance after a solid third quarter beat and raise on Friday, with the stronger full year outlook reflecting better than expected core performance, as well as incremental earnings from state supplemental programs. Importantly, management appears to be voicing greater confidence in its ability to achieve volume growth next year in line with long-term targets, even in a scenario where enhanced ACA exchange subsidies are allowed to expire, thanks to continued strong demographics and expanded patient access, particularly ambulatory. Maintaining OP and raising our PT to $482 (previously $449) on revised estimates."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• SpaceX files for 555.56M share IPO at $135/sh
• BTIG Upgrades Medtronic, Inc. (MDT) to Buy